Thread by @Biotech2k1

Taking a Look at $PACB:

An updated look at Pacific Biosciences.

1/ I prefix this as sequencing companies is not in my space of expertise so my numbers or expectations may be off. I do like the company as my play on sequencing in the Genomics space.

2/ Management

I have been in Pacific Biosciences for only a short time, but I think Christian Henry is doing good so far. It will take a while to really know how good he really is at running this company.

3/ Science

They make the machines and consumables for sequencing DNA. They are commercial with their long read sequencing. They bought Omniome which is developing short read sequencing. I think together they will offer a good balance of both technologies.

4/ Potential

I am not an expert in the sequencing space, but I think they could grow their market share to around $1 billion in long term revenues as they continue to grow in long read and expand into short read.

5/ Value

I think they offer a good value down here at $2.27 billion market cap. They have $1 billion in cash and burned about $181 million in 2021. They have plenty of cash for 2 years. They have $130 million in 2021 revenues growing 65% year over year.